[August 11, 2011] GNS enters into agreement with Bristol-Myers to identify molecular mechanisms Tweet Aug 11, 2011 (Datamonitor via COMTEX) -- GNS Healthcare, Inc., a subsidiary of Via Science, has entered into a collaboration with Bristol-Myers Squibb Company. Under this agreement, using its supercomputer-driven reverse-engineering and forward-simulation, or REFS, platform, GNS will use clinical and molecular information from a Bristol-Myers Squibb clinical trial to build computer models to identify key molecular mechanisms. Financial terms of the agreement were not disclosed. Using patient data comprised of genetic information, gene expression levels, specific blood markers and clinical outcomes researchers will use REFS to construct a comprehensive inflammation disease model directly from the raw data. The resulting disease model is intended to support virtual clinical trials that will simulate the clinical effect of inhibiting various drug targets and help predict novel molecular targets to combat immuno-inflammation that would be effective for specific types of patients. "We are pleased to be working with Bristol-Myers Squibb to identify biomarkers in immuno-inflammation," said Dr Iya Khalil, Executive vice president and co-founder of GNS Healthcare. "This is the first step in building a significantly advanced in silico research paradigm that may enable development of new therapies based directly on human data, and address the needs of patients with particular genetics and molecular phenotypes, ultimately enabling the optimization of individualized patient outcomes." http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon [ Back To TMCnet.com's Homepage ]